Antiphospholipid Antibodies Modify the Prognostic Value of Baseline Platelet Count for Clinical Outcomes After Ischemic Stroke

Antiphospholipid antibodies (aPLs) have been reported to be involved in platelet-mediated thrombosis and inflammation, but the impact on the prognosis of ischemic stroke remains unclear. We aimed to examine whether the association between baseline platelet count (PLT) and long-term clinical outcomes...

Full description

Saved in:
Bibliographic Details
Published inJournal of the American Heart Association Vol. 13; no. 19; p. e035183
Main Authors Wang, Yinan, Yang, Pinni, Zhu, Zhengbao, Peng, Hao, Bu, Xiaoqing, Xu, Qingyun, Wang, Aili, Chen, Jing, Xu, Tan, Zhang, Yonghong, He, Jiang
Format Journal Article
LanguageEnglish
Published England John Wiley and Sons Inc 01.10.2024
Wiley
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Antiphospholipid antibodies (aPLs) have been reported to be involved in platelet-mediated thrombosis and inflammation, but the impact on the prognosis of ischemic stroke remains unclear. We aimed to examine whether the association between baseline platelet count (PLT) and long-term clinical outcomes within 2 years after ischemic stroke onset is modulated by aPLs. A total of 2938 patients with ischemic stroke were included in this prospective cohort study. Cox proportional hazards regression models were used to assess the association between the baseline PLT stratified by aPLs status and 2-year clinical outcomes after stroke onset, and an interaction effect between PLT and aPLs on clinical outcomes was tested by likelihood ratio test. There was a significant interaction effect of aPLs and PLT on recurrent stroke ( =0.002) and cardiovascular events ( =0.001) within 2 years after stroke onset. After multivariate adjustment, high PLT was associated with increased risks of recurrent stroke (hazard ratio [HR], 2.78 [95% CI, 1.03-7.45]; =0.039) and cardiovascular events (HR, 2.58 [95% CI, 1.12-5.90]; =0.024) when 2 extreme tertiles were compared among patients with aPL positive, but not among those with aPL negative. The aPLs had a modifying effect on the association between PLT and clinical outcomes within 2 years after ischemic stroke onset. Increased PLT was associated with recurrent stroke and cardiovascular events after ischemic stroke onset among patients with aPL positive, but not in those with aPL negative.
AbstractList Antiphospholipid antibodies (aPLs) have been reported to be involved in platelet-mediated thrombosis and inflammation, but the impact on the prognosis of ischemic stroke remains unclear. We aimed to examine whether the association between baseline platelet count (PLT) and long-term clinical outcomes within 2 years after ischemic stroke onset is modulated by aPLs. A total of 2938 patients with ischemic stroke were included in this prospective cohort study. Cox proportional hazards regression models were used to assess the association between the baseline PLT stratified by aPLs status and 2-year clinical outcomes after stroke onset, and an interaction effect between PLT and aPLs on clinical outcomes was tested by likelihood ratio test. There was a significant interaction effect of aPLs and PLT on recurrent stroke ( =0.002) and cardiovascular events ( =0.001) within 2 years after stroke onset. After multivariate adjustment, high PLT was associated with increased risks of recurrent stroke (hazard ratio [HR], 2.78 [95% CI, 1.03-7.45]; =0.039) and cardiovascular events (HR, 2.58 [95% CI, 1.12-5.90]; =0.024) when 2 extreme tertiles were compared among patients with aPL positive, but not among those with aPL negative. The aPLs had a modifying effect on the association between PLT and clinical outcomes within 2 years after ischemic stroke onset. Increased PLT was associated with recurrent stroke and cardiovascular events after ischemic stroke onset among patients with aPL positive, but not in those with aPL negative.
Antiphospholipid antibodies (aPLs) have been reported to be involved in platelet-mediated thrombosis and inflammation, but the impact on the prognosis of ischemic stroke remains unclear. We aimed to examine whether the association between baseline platelet count (PLT) and long-term clinical outcomes within 2 years after ischemic stroke onset is modulated by aPLs.BACKGROUNDAntiphospholipid antibodies (aPLs) have been reported to be involved in platelet-mediated thrombosis and inflammation, but the impact on the prognosis of ischemic stroke remains unclear. We aimed to examine whether the association between baseline platelet count (PLT) and long-term clinical outcomes within 2 years after ischemic stroke onset is modulated by aPLs.A total of 2938 patients with ischemic stroke were included in this prospective cohort study. Cox proportional hazards regression models were used to assess the association between the baseline PLT stratified by aPLs status and 2-year clinical outcomes after stroke onset, and an interaction effect between PLT and aPLs on clinical outcomes was tested by likelihood ratio test. There was a significant interaction effect of aPLs and PLT on recurrent stroke (Pinteraction=0.002) and cardiovascular events (Pinteraction=0.001) within 2 years after stroke onset. After multivariate adjustment, high PLT was associated with increased risks of recurrent stroke (hazard ratio [HR], 2.78 [95% CI, 1.03-7.45]; Ptrend=0.039) and cardiovascular events (HR, 2.58 [95% CI, 1.12-5.90]; Ptrend=0.024) when 2 extreme tertiles were compared among patients with aPL positive, but not among those with aPL negative.METHODS AND RESULTSA total of 2938 patients with ischemic stroke were included in this prospective cohort study. Cox proportional hazards regression models were used to assess the association between the baseline PLT stratified by aPLs status and 2-year clinical outcomes after stroke onset, and an interaction effect between PLT and aPLs on clinical outcomes was tested by likelihood ratio test. There was a significant interaction effect of aPLs and PLT on recurrent stroke (Pinteraction=0.002) and cardiovascular events (Pinteraction=0.001) within 2 years after stroke onset. After multivariate adjustment, high PLT was associated with increased risks of recurrent stroke (hazard ratio [HR], 2.78 [95% CI, 1.03-7.45]; Ptrend=0.039) and cardiovascular events (HR, 2.58 [95% CI, 1.12-5.90]; Ptrend=0.024) when 2 extreme tertiles were compared among patients with aPL positive, but not among those with aPL negative.The aPLs had a modifying effect on the association between PLT and clinical outcomes within 2 years after ischemic stroke onset. Increased PLT was associated with recurrent stroke and cardiovascular events after ischemic stroke onset among patients with aPL positive, but not in those with aPL negative.CONCLUSIONSThe aPLs had a modifying effect on the association between PLT and clinical outcomes within 2 years after ischemic stroke onset. Increased PLT was associated with recurrent stroke and cardiovascular events after ischemic stroke onset among patients with aPL positive, but not in those with aPL negative.
Background Antiphospholipid antibodies (aPLs) have been reported to be involved in platelet‐mediated thrombosis and inflammation, but the impact on the prognosis of ischemic stroke remains unclear. We aimed to examine whether the association between baseline platelet count (PLT) and long‐term clinical outcomes within 2 years after ischemic stroke onset is modulated by aPLs. Methods and Results A total of 2938 patients with ischemic stroke were included in this prospective cohort study. Cox proportional hazards regression models were used to assess the association between the baseline PLT stratified by aPLs status and 2‐year clinical outcomes after stroke onset, and an interaction effect between PLT and aPLs on clinical outcomes was tested by likelihood ratio test. There was a significant interaction effect of aPLs and PLT on recurrent stroke (Pinteraction=0.002) and cardiovascular events (Pinteraction=0.001) within 2 years after stroke onset. After multivariate adjustment, high PLT was associated with increased risks of recurrent stroke (hazard ratio [HR], 2.78 [95% CI, 1.03–7.45]; Ptrend=0.039) and cardiovascular events (HR, 2.58 [95% CI, 1.12–5.90]; Ptrend=0.024) when 2 extreme tertiles were compared among patients with aPL positive, but not among those with aPL negative. Conclusions The aPLs had a modifying effect on the association between PLT and clinical outcomes within 2 years after ischemic stroke onset. Increased PLT was associated with recurrent stroke and cardiovascular events after ischemic stroke onset among patients with aPL positive, but not in those with aPL negative.
Author Peng, Hao
Wang, Aili
Zhu, Zhengbao
Wang, Yinan
Yang, Pinni
Xu, Tan
Zhang, Yonghong
Bu, Xiaoqing
Xu, Qingyun
He, Jiang
Chen, Jing
AuthorAffiliation 5 Department of Medicine Tulane University School of Medicine New Orleans LA USA
2 Ningbo Municipal Center for Disease Control and Prevention Ningbo China
4 Department of Epidemiology, School of Public Health Chongqing Medical University Chongqing China
3 Department of Epidemiology Tulane University School of Public Health and Tropical Medicine New Orleans LA USA
1 Department of Epidemiology, School of Public Health and Jiangsu Key Laboratory of Preventive and Translational Medicine for Major Chronic Non‐communicable Diseases Suzhou Medical College of Soochow University Suzhou China
AuthorAffiliation_xml – name: 1 Department of Epidemiology, School of Public Health and Jiangsu Key Laboratory of Preventive and Translational Medicine for Major Chronic Non‐communicable Diseases Suzhou Medical College of Soochow University Suzhou China
– name: 2 Ningbo Municipal Center for Disease Control and Prevention Ningbo China
– name: 4 Department of Epidemiology, School of Public Health Chongqing Medical University Chongqing China
– name: 5 Department of Medicine Tulane University School of Medicine New Orleans LA USA
– name: 3 Department of Epidemiology Tulane University School of Public Health and Tropical Medicine New Orleans LA USA
Author_xml – sequence: 1
  givenname: Yinan
  orcidid: 0000-0003-2967-6058
  surname: Wang
  fullname: Wang, Yinan
  organization: Department of Epidemiology, School of Public Health and Jiangsu Key Laboratory of Preventive and Translational Medicine for Major Chronic Non‐communicable Diseases Suzhou Medical College of Soochow University Suzhou China, Ningbo Municipal Center for Disease Control and Prevention Ningbo China
– sequence: 2
  givenname: Pinni
  orcidid: 0000-0001-7327-3294
  surname: Yang
  fullname: Yang, Pinni
  organization: Department of Epidemiology, School of Public Health and Jiangsu Key Laboratory of Preventive and Translational Medicine for Major Chronic Non‐communicable Diseases Suzhou Medical College of Soochow University Suzhou China
– sequence: 3
  givenname: Zhengbao
  orcidid: 0000-0001-5500-0014
  surname: Zhu
  fullname: Zhu, Zhengbao
  organization: Department of Epidemiology, School of Public Health and Jiangsu Key Laboratory of Preventive and Translational Medicine for Major Chronic Non‐communicable Diseases Suzhou Medical College of Soochow University Suzhou China, Department of Epidemiology Tulane University School of Public Health and Tropical Medicine New Orleans LA USA
– sequence: 4
  givenname: Hao
  orcidid: 0000-0001-6277-662X
  surname: Peng
  fullname: Peng, Hao
  organization: Department of Epidemiology, School of Public Health and Jiangsu Key Laboratory of Preventive and Translational Medicine for Major Chronic Non‐communicable Diseases Suzhou Medical College of Soochow University Suzhou China
– sequence: 5
  givenname: Xiaoqing
  orcidid: 0009-0007-4581-0444
  surname: Bu
  fullname: Bu, Xiaoqing
  organization: Department of Epidemiology, School of Public Health Chongqing Medical University Chongqing China
– sequence: 6
  givenname: Qingyun
  surname: Xu
  fullname: Xu, Qingyun
  organization: Department of Epidemiology, School of Public Health and Jiangsu Key Laboratory of Preventive and Translational Medicine for Major Chronic Non‐communicable Diseases Suzhou Medical College of Soochow University Suzhou China
– sequence: 7
  givenname: Aili
  surname: Wang
  fullname: Wang, Aili
  organization: Department of Epidemiology, School of Public Health and Jiangsu Key Laboratory of Preventive and Translational Medicine for Major Chronic Non‐communicable Diseases Suzhou Medical College of Soochow University Suzhou China
– sequence: 8
  givenname: Jing
  orcidid: 0000-0002-9035-9126
  surname: Chen
  fullname: Chen, Jing
  organization: Department of Epidemiology Tulane University School of Public Health and Tropical Medicine New Orleans LA USA, Department of Medicine Tulane University School of Medicine New Orleans LA USA
– sequence: 9
  givenname: Tan
  surname: Xu
  fullname: Xu, Tan
  organization: Department of Epidemiology, School of Public Health and Jiangsu Key Laboratory of Preventive and Translational Medicine for Major Chronic Non‐communicable Diseases Suzhou Medical College of Soochow University Suzhou China
– sequence: 10
  givenname: Yonghong
  orcidid: 0000-0001-6188-3490
  surname: Zhang
  fullname: Zhang, Yonghong
  organization: Department of Epidemiology, School of Public Health and Jiangsu Key Laboratory of Preventive and Translational Medicine for Major Chronic Non‐communicable Diseases Suzhou Medical College of Soochow University Suzhou China
– sequence: 11
  givenname: Jiang
  orcidid: 0000-0002-8286-9652
  surname: He
  fullname: He, Jiang
  organization: Department of Epidemiology Tulane University School of Public Health and Tropical Medicine New Orleans LA USA, Department of Medicine Tulane University School of Medicine New Orleans LA USA
BackLink https://www.ncbi.nlm.nih.gov/pubmed/39344638$$D View this record in MEDLINE/PubMed
BookMark eNp1kstv1DAQhyNUREvpmRvykctu_U5yQmEFdFFRkXhcLduZ7Lo48dZ2kHrhb8fLtqhFwpI1o3l8P1szz6ujKUxQVS8JXhIiyfnH7qJbEsqXmAnSsCfVCcW8XrRtg48e-MfVWUrXuBxJaybaZ9UxaxnnkjUn1a9uym63Dalc73auR_uACb2DhD4VM9yivAX0OYbNFFJ2Fn3XfgYUBvRWJ_BuKkmvM3jIaBXmKaMhRLQqCWe1R1dztmEssG7IENE62S2MhfIlx_ADXlRPB-0TnN3Z0-rb-3dfVxeLy6sP61V3ubBc4rwAKlppmalBWMH7AQsJRnBhodWSid5iSg1hAHRg3BqrW0ZaTnDNqZGEYnZarQ_cPuhrtYtu1PFWBe3Un0CIG6Vj-ZwHBTU2tAcprTbcNtQYgQfMhWFFvW6awnpzYO1mM0JvYcpR-0fQx5nJbdUm_FRlaA3hdVsIr-8IMdzMkLIaXbLgvZ4gzEkxQsqjaY1lKX31UOyvyv0ES4E4FNgYUoowKOuyzi7stZ1XBO91idoviyrLog7LUvrO_-m7R_-v4zfJd8II
CitedBy_id crossref_primary_10_1016_j_vph_2025_107474
Cites_doi 10.1111/j.1538-7836.2009.03446.x
10.1093/rheumatology/key340
10.1212/WNL.43.10.2069
10.1212/01.WNL.0000086809.46485.A1
10.3390/ijms22084200
10.1161/01.STR.20.7.864
10.1159/000048623
10.1161/01.CIR.0000154900.76284.F6
10.1515/cclm-2022-0317
10.1161/STROKEAHA.114.005380
10.1182/blood-2016-07-692673
10.1182/blood-2014-02-554980
10.1161/CIRCULATIONAHA.116.025250
10.1161/01.STR.0000087149.42294.8C
10.1002/cphy.c170049
10.1196/annals.1361.083
10.1212/WNL.51.3_Suppl_3.S9
10.1161/CIRCULATIONAHA.105.548495
10.1212/WNL.0000000000010105
10.1161/STR.0000000000000375
10.1016/j.jns.2016.01.044
10.1016/S1474-4422(21)00252-0
10.1111/j.1538-7836.2007.02310.x
10.1016/j.jaut.2022.102813
10.1161/01.STR.32.8.1701
10.1177/1076029614550820
10.1161/01.STR.24.1.35
10.1111/ijlh.12474
10.1161/STROKEAHA.116.013827
10.1212/WNL.48.1.91
10.1055/s-0028-1082267
10.1161/STROKEAHA.107.189063
10.1111/j.1538-7836.2006.01753.x
10.1160/TH03-10-0608
10.1007/978-3-319-19425-7
10.1016/j.blre.2020.100788
10.1007/s11926-014-0494-8
10.1378/chest.11-2302
10.1002/sim.4780080504
10.3389/fneur.2019.00370
10.1001/jama.2013.282543
10.1002/sim.2929
ContentType Journal Article
Copyright 2024 The Author(s). Published on behalf of the American Heart Association, Inc., by Wiley.
Copyright_xml – notice: 2024 The Author(s). Published on behalf of the American Heart Association, Inc., by Wiley.
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7X8
5PM
DOA
DOI 10.1161/JAHA.124.035183
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ Directory of Open Access Journals
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList MEDLINE
MEDLINE - Academic

Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 3
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
DocumentTitleAlternate aPLs Modify the Association Between PLT and Stroke Prognosis
EISSN 2047-9980
ExternalDocumentID oai_doaj_org_article_e70b2de66cab4c82bb50f045b37e5788
PMC11681479
39344638
10_1161_JAHA_124_035183
Genre Journal Article
GroupedDBID 0R~
1OC
24P
53G
5VS
8-1
AAYXX
AAZKR
ACCMX
ACGFO
ACXQS
ADBBV
ADKYN
ADRAZ
ADZMN
AEGXH
AENEX
AIAGR
ALAGY
ALMA_UNASSIGNED_HOLDINGS
AOIJS
AVUZU
BAWUL
BCNDV
CITATION
DIK
EBS
EJD
EMOBN
GODZA
GROUPED_DOAJ
GX1
H13
HYE
KQ8
M48
M~E
OK1
RAH
RNS
RPM
CGR
CUY
CVF
ECM
EIF
NPM
RHF
WIN
7X8
AAMMB
AEFGJ
AGXDD
AIDQK
AIDYY
5PM
ID FETCH-LOGICAL-c460t-e2596c3b7e5c54df056eb545ce9a635dc022b13ee2f34cbca9319410742b61203
IEDL.DBID M48
ISSN 2047-9980
IngestDate Wed Aug 27 01:25:33 EDT 2025
Thu Aug 21 18:29:49 EDT 2025
Thu Jul 10 22:32:23 EDT 2025
Wed Feb 19 02:00:25 EST 2025
Tue Jul 01 03:15:45 EDT 2025
Thu Apr 24 23:05:21 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 19
Keywords platelet count
prognosis
antiphospholipid antibodies
ischemic stroke
Language English
License This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c460t-e2596c3b7e5c54df056eb545ce9a635dc022b13ee2f34cbca9319410742b61203
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
This manuscript was sent to Jose R. Romero, MD, Associate Editor, for review by expert referees, editorial decision, and final disposition.
Supplemental Material is available at https://www.ahajournals.org/doi/suppl/10.1161/JAHA.124.035183
For Sources of Funding and Disclosures, see page 9.
ORCID 0009-0007-4581-0444
0000-0001-7327-3294
0000-0001-6188-3490
0000-0001-5500-0014
0000-0001-6277-662X
0000-0002-9035-9126
0000-0002-8286-9652
0000-0003-2967-6058
OpenAccessLink http://journals.scholarsportal.info/openUrl.xqy?doi=10.1161/JAHA.124.035183
PMID 39344638
PQID 3111202706
PQPubID 23479
ParticipantIDs doaj_primary_oai_doaj_org_article_e70b2de66cab4c82bb50f045b37e5788
pubmedcentral_primary_oai_pubmedcentral_nih_gov_11681479
proquest_miscellaneous_3111202706
pubmed_primary_39344638
crossref_citationtrail_10_1161_JAHA_124_035183
crossref_primary_10_1161_JAHA_124_035183
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2024-10-01
PublicationDateYYYYMMDD 2024-10-01
PublicationDate_xml – month: 10
  year: 2024
  text: 2024-10-01
  day: 01
PublicationDecade 2020
PublicationPlace England
PublicationPlace_xml – name: England
– name: Hoboken
PublicationTitle Journal of the American Heart Association
PublicationTitleAlternate J Am Heart Assoc
PublicationYear 2024
Publisher John Wiley and Sons Inc
Wiley
Publisher_xml – name: John Wiley and Sons Inc
– name: Wiley
References e_1_3_2_26_2
e_1_3_2_27_2
e_1_3_2_28_2
e_1_3_2_29_2
e_1_3_2_41_2
e_1_3_2_40_2
e_1_3_2_20_2
e_1_3_2_43_2
e_1_3_2_21_2
e_1_3_2_42_2
e_1_3_2_22_2
e_1_3_2_23_2
e_1_3_2_24_2
e_1_3_2_25_2
e_1_3_2_9_2
e_1_3_2_15_2
e_1_3_2_38_2
e_1_3_2_8_2
e_1_3_2_16_2
e_1_3_2_37_2
e_1_3_2_7_2
e_1_3_2_17_2
e_1_3_2_6_2
e_1_3_2_18_2
e_1_3_2_39_2
e_1_3_2_19_2
e_1_3_2_30_2
e_1_3_2_32_2
e_1_3_2_10_2
e_1_3_2_31_2
e_1_3_2_5_2
e_1_3_2_11_2
e_1_3_2_34_2
e_1_3_2_4_2
e_1_3_2_12_2
e_1_3_2_33_2
e_1_3_2_3_2
e_1_3_2_13_2
e_1_3_2_36_2
e_1_3_2_2_2
e_1_3_2_14_2
e_1_3_2_35_2
References_xml – ident: e_1_3_2_31_2
  doi: 10.1111/j.1538-7836.2009.03446.x
– ident: e_1_3_2_30_2
  doi: 10.1093/rheumatology/key340
– ident: e_1_3_2_33_2
  doi: 10.1212/WNL.43.10.2069
– ident: e_1_3_2_13_2
  doi: 10.1212/01.WNL.0000086809.46485.A1
– ident: e_1_3_2_16_2
  doi: 10.3390/ijms22084200
– ident: e_1_3_2_18_2
  doi: 10.1161/01.STR.20.7.864
– ident: e_1_3_2_14_2
  doi: 10.1159/000048623
– ident: e_1_3_2_19_2
  doi: 10.1161/01.CIR.0000154900.76284.F6
– ident: e_1_3_2_24_2
  doi: 10.1515/cclm-2022-0317
– ident: e_1_3_2_41_2
  doi: 10.1161/STROKEAHA.114.005380
– ident: e_1_3_2_6_2
  doi: 10.1182/blood-2016-07-692673
– ident: e_1_3_2_34_2
  doi: 10.1182/blood-2014-02-554980
– ident: e_1_3_2_2_2
  doi: 10.1161/CIRCULATIONAHA.116.025250
– ident: e_1_3_2_4_2
  doi: 10.1161/01.STR.0000087149.42294.8C
– ident: e_1_3_2_5_2
  doi: 10.1002/cphy.c170049
– ident: e_1_3_2_38_2
  doi: 10.1196/annals.1361.083
– ident: e_1_3_2_7_2
  doi: 10.1212/WNL.51.3_Suppl_3.S9
– ident: e_1_3_2_11_2
  doi: 10.1161/CIRCULATIONAHA.105.548495
– ident: e_1_3_2_43_2
  doi: 10.1212/WNL.0000000000010105
– ident: e_1_3_2_40_2
  doi: 10.1161/STR.0000000000000375
– ident: e_1_3_2_10_2
  doi: 10.1016/j.jns.2016.01.044
– ident: e_1_3_2_3_2
  doi: 10.1016/S1474-4422(21)00252-0
– ident: e_1_3_2_35_2
  doi: 10.1111/j.1538-7836.2007.02310.x
– ident: e_1_3_2_15_2
  doi: 10.1016/j.jaut.2022.102813
– ident: e_1_3_2_32_2
  doi: 10.1161/01.STR.32.8.1701
– ident: e_1_3_2_9_2
  doi: 10.1177/1076029614550820
– ident: e_1_3_2_20_2
  doi: 10.1161/01.STR.24.1.35
– ident: e_1_3_2_25_2
  doi: 10.1111/ijlh.12474
– ident: e_1_3_2_12_2
  doi: 10.1161/STROKEAHA.116.013827
– ident: e_1_3_2_42_2
  doi: 10.1212/WNL.48.1.91
– ident: e_1_3_2_39_2
  doi: 10.1055/s-0028-1082267
– ident: e_1_3_2_26_2
  doi: 10.1161/STROKEAHA.107.189063
– ident: e_1_3_2_28_2
  doi: 10.1111/j.1538-7836.2006.01753.x
– ident: e_1_3_2_36_2
  doi: 10.1160/TH03-10-0608
– ident: e_1_3_2_22_2
  doi: 10.1007/978-3-319-19425-7
– ident: e_1_3_2_29_2
  doi: 10.1016/j.blre.2020.100788
– ident: e_1_3_2_37_2
  doi: 10.1007/s11926-014-0494-8
– ident: e_1_3_2_27_2
  doi: 10.1378/chest.11-2302
– ident: e_1_3_2_21_2
  doi: 10.1002/sim.4780080504
– ident: e_1_3_2_8_2
  doi: 10.3389/fneur.2019.00370
– ident: e_1_3_2_17_2
  doi: 10.1001/jama.2013.282543
– ident: e_1_3_2_23_2
  doi: 10.1002/sim.2929
SSID ssj0000627359
Score 2.360803
Snippet Antiphospholipid antibodies (aPLs) have been reported to be involved in platelet-mediated thrombosis and inflammation, but the impact on the prognosis of...
Background Antiphospholipid antibodies (aPLs) have been reported to be involved in platelet‐mediated thrombosis and inflammation, but the impact on the...
SourceID doaj
pubmedcentral
proquest
pubmed
crossref
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Enrichment Source
StartPage e035183
SubjectTerms Aged
Antibodies, Antiphospholipid - blood
antiphospholipid antibodies
Biomarkers - blood
Blood Platelets - immunology
Female
Humans
ischemic stroke
Ischemic Stroke - blood
Ischemic Stroke - diagnosis
Ischemic Stroke - immunology
Male
Middle Aged
Original Research
Platelet Count
Predictive Value of Tests
Prognosis
Prospective Studies
Recurrence
Risk Assessment
Risk Factors
Time Factors
SummonAdditionalLinks – databaseName: DOAJ Directory of Open Access Journals
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1LT9wwELYqDlUviL5gW1oZqQcugSR2nOS4VEUL0rZILRU3y2OPxapRslqyBy78dsZJWO0iKi4cokjxI45nnPnGHn9m7JsqQKDJVKSsc5GU0kSFdybyMaTCQQLQUQpNf6rJpTy_yq7WjvoKMWE9PXDfcceYUymHSlkD0hYpQBZ7wiEgciRt67b5ks1bc6b6fzCZ5awcuHwI1Ryfjydh4k8ehaWzQmyYoY6t_ymI-ThScs30nO6w7QEz8nHf1rfsFdbv2OvpsCr-nt2N63Y2v25u6Kpm85nj4QE0IUCQT-nmbznhPH6xaEJYHdXC_5pqibzx_MR0O9IpsSLUSULkYZd6ywnL8oEztOK_li0pJlU2DieK8zPyiENMPf_dLpp_-IFdnv74830SDecqRFaquI2QXB5lBVAH2kw6TxgIgZCUxdIQ_nCW7DokAjH1QlqwpqRxKkPkZgoEiGLxkW3VTY17jAM4753yeW5LqSSWKWZl4UyBSWqlhBE7euhmbQfS8XD2RaU750MlOshFk1x0L5cRO1wVmPd8G__PehLktsoWiLK7B6Q-elAf_Zz6jNjBg9Q1DaywWmJqbJY3WpAVCDNDsRqx3V4LVq8SpSA3WlDpYkM_NtqymVLPrjvybvqSIpF5-eklWv-ZvaEmyj64cJ9ttYslfiGQ1MLXbjzcA_I4Edg
  priority: 102
  providerName: Directory of Open Access Journals
Title Antiphospholipid Antibodies Modify the Prognostic Value of Baseline Platelet Count for Clinical Outcomes After Ischemic Stroke
URI https://www.ncbi.nlm.nih.gov/pubmed/39344638
https://www.proquest.com/docview/3111202706
https://pubmed.ncbi.nlm.nih.gov/PMC11681479
https://doaj.org/article/e70b2de66cab4c82bb50f045b37e5788
Volume 13
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwdV1Lb9QwELagSFUvqLxDHzISBy5ZkthxnANCW0S1VFpAgkW9RR4_2hVRsmSzEr3w2xkn2aWLtocokp-xZybz2R7PEPJaSGBWpSIU2piQc65C6YwKXQQJMxADdC6Fpp_FZMYvLtPLf-GAhglc7lza-XhSs6Yc_f518x4F_l0n8CJ-ezGe-D09PvKnYpLdJw9QLWU-nMF0wPr9bxk1dZoP7n121Dsg-yxnuDzyd1VuKanOl_8uAPq_HeUtxXR-SB4OiJKOexZ4RO7Z6jHZnw5n5k_In3HVzhfX9RKfcr6YG-oToPbmg3SKL3dDEQXSr03tje6wFfpDlStLa0fPVHdfHTNLxKRIYurvsLcUkS4dPIqW9MuqRbbFxsY-3jj9hJPqLe7pt7apf9qnZHb-8fuHSThEXQg1F1EbWlwQCc0gs6lOuXGIkCwgztI2V4hOjEatDzGzNnGMa9AqRynm3q4zAYRLEXtG9qq6si8IBTDOGeGyTOdccJsnNs2lUdLGieYcAjJaT3OhB5fkPjJGWXRLExEXnkQFkqjoSRSQN5sKi94bx91FzzzdNsW8G-0uoW6uikEqC5shSxorhFbAtUwA0sghyAWGo8-kDMirNdULFDt_lqIqW6-WBUMd4feNIhGQ5z0XbLpac1FA5BZ_bH3Ldk41v-5ce-NIZMyz_OWdjR6RA-yX9_aEx2SvbVb2BHFRC6fdfsJpx_V_AbaBDE8
linkProvider Scholars Portal
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Antiphospholipid+Antibodies+Modify+the+Prognostic+Value+of+Baseline+Platelet+Count+for+Clinical+Outcomes+After+Ischemic+Stroke&rft.jtitle=Journal+of+the+American+Heart+Association&rft.au=Wang%2C+Yinan&rft.au=Yang%2C+Pinni&rft.au=Zhu%2C+Zhengbao&rft.au=Peng%2C+Hao&rft.date=2024-10-01&rft.eissn=2047-9980&rft.volume=13&rft.issue=19&rft.spage=e035183&rft_id=info:doi/10.1161%2FJAHA.124.035183&rft_id=info%3Apmid%2F39344638&rft.externalDocID=39344638
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2047-9980&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2047-9980&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2047-9980&client=summon